Haris Ali, M.D.

Haris Ali, M.D., joined the Department of Hematology and Hematopoietic Cell Transplantation (HCT) as assistant professor following the completion of his HCT fellowship here at City of Hope. Dr. Ali received his medical doctorate from Rawalpindi Medical College in Rawalpindi, Pakistan.

 

He completed an internal medicine internship at the University of Maryland's Harbor Hospital Center in Baltimore, followed by an internal medicine residency at Loma Linda University Medical Center, where he eventually was named chief resident and then stayed on for the next four years as an Instructor, and then Assistant Professor of Medicine.

 

Dr. Ali then decided to continue his training, completing a medical oncology/hematology fellowship at the University of Texas Southwestern Medical Center in Dallas, Texas, before coming to City of Hope. During his fellowship, Dr. Ali received the Recognition Award for First Place in American Society of Clinical Oncology In-Service in 2011 and 2012, and the Recognition Award for First Place in American Society of Hematology In-Service Exam also in 2011 and 2012. 

 

Dr. Ali is board-certified in internal medicine, medical oncology and hematology and available to see our patients with hematologic malignancy and BMT. He is a Fellow of the American College of Physicians.

Display all publications

• Fifty years of BMT: risk stratification, donor matching, and stem cell collection for transplantation.Salhotra, A., Yuan, S., & Ali, H. (2023). Frontiers in oncology, 13, 1196564.
• Ponatinib, asciminib and inotuzumab ozogamicin: A novel drug combination in acute lymphoblastic leukemia. Tinajero, J., Koller, P., & Ali, H. (2023). Leukemia research, 129, 107299.
• The impact of SARS-CoV2 vaccines on the incidence of graft versus host disease in allogeneic hematopoietic stem cell transplant recipients: a single-center retrospective study. Ngo, D., Chen, J., Tinajero, J., Aribi, A., Arslan, S., Marcucci, G., Nakamura, R., Al Malki, M. M., Forman, S. J., Dadwal, S., & Ali, H. (2023). Stem cell research & therapy, 14(1), 95.
• Biology and Current Treatment of Myeloproliferative Neoplasms. Ali, H., Pullarkat, V., & Snyder, D. (2021). Cancer treatment and research, 181, 151–165.
• Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study. Ali, H., Tsai, N. C., Synold, T., Mokhtari, S., Tsia, W., Palmer, J., Stiller, T., Al Malki, M., Aldoss, I., Salhotra, A., Rahmanuddin, S., Pullarkat, V., Cai, J. L., Stein, A., Forman, S. J., Marcucci, G., Mei, M., Snyder, D. S., & Nakamura, R. (2022). Blood advances, 6(5), 1444–1453.
• 2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management. Ali, H., & Bacigalupo, A. (2021). American journal of hematology, 96(11), 1532–1538.
• MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen. Ali, H., Aldoss, I., Yang, D., Mokhtari, S., Khaled, S., Aribi, A., Afkhami, M., Al Malki, M. M., Cao, T., Mei, M., O'Donnell, M., Salhotra, A., Pullarkat, V., Yang, L., Stein, A. S., Marcucci, G., Forman, S. J., Nakamura, R., Pillai, R., & Snyder, D. (2019). Blood advances, 3(1), 83–95.
• Ruxolitinib for the treatment of graft-versus-host disease. Ali, H., Salhotra, A., Modi, B., & Nakamura, R. (2020). Expert review of clinical immunology, 16(4), 347–359.
• Efficacy of blinatumomab for MRD relapse in ALL post allogenic HCT. Ali, H., Salhotra, A., Stein, A. S., Nakamura, R., Marcucci, G., Forman, S. J., Pullarkat, V., & Aldoss, I. (2021). Leukemia research, 104, 106579.
• Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients. Ali, H., Ngo, D., Aribi, A., Arslan, S., Dadwal, S., Marcucci, G., Nakamura, R., Forman, S. J., Chen, J., & Al Malki, M. M. (2021). Transplantation and cellular therapy, 27(11), 938.e1–938.e6.
• A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement. Mehta RS, Ali H, Dai Y, Yao B, Overman B, Ratanatharathorn V, Gill S, Socié G, Anderson K, Cahn JY, Mujeebuddin A, Champlin R, Shpall E, Holtan SG, Alousi A. Bone Marrow Transplant. 2023 May 18:1-9. doi: 10.1038/s41409-023-01996-4. Online ahead of print. PMID: 37202544 Free PMC article.
• Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis.Yao JM, Otoukesh S, Kim H, Yang D, Mokhtari S, Samara Y, Blackmon A, Arslan S, Agrawal V, Pourhassan H, Amanam I, Ball B, Koller P, Salhotra A, Becker P, Curtin P, Artz A, Aldoss I, Ali H, Stewart F, Smith E, Stein A, Marcucci G, Forman SJ, Nakamura R, Al Malki MM. Transplant Cell Ther. 2023 May 12:S2666-6367(23)01291-5. doi: 10.1016/j.jtct.2023.05.008. Online ahead of print. PMID: 37182736
• A Simple Prognostic System in Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplant: A CIBMTR/EBMT analysis. Tamari R, McLornan DP, Ahn KW, Estrada-Merly N, Hernandez-Boluda JC, Giralt SA, Palmer JM, Gale RP, DeFilipp Z, Marks D, van der Poel MWM, Verdonck LF, Battiwalla M, Díaz MA, Gupta V, Ali H, Litzow MR, Lazarus HM, Gergis U, Bashey A, Liesveld JL, Hashmi S, Pu JJ, Beitinjaneh A, Bredeson CN, Rizzieri DA, Savani BN, Abid MB, Ganguly S, Agrawal V, Ulrike V, Wirk B, Jain T, Cutler CS, Aljurf M, Kindwall-Keller T, Kharfan-Dabaja MA, Hildebrandt GC, Pawarode A, Solh MM, Yared JA, Grunwald MR, Nathan S, Nishihori T, Seo S, Scott BL, Nakamura R, Oran B, Czerw T, Yakoub-Agha I, Saber W. Blood Adv. 2023 May 3:bloodadvances.2023009886. doi: 10.1182/bloodadvances.2023009886. Online ahead of print. PMID: 37134306
• Ponatinib, asciminib and inotuzumab ozogamicin: A novel drug combination in acute lymphoblastic leukemia. Tinajero J, Koller P, Ali H. Leuk Res. 2023 Jun;129:107299. doi: 10.1016/j.leukres.2023.107299. Epub 2023 Apr 23. PMID: 37120933 No abstract available.
• Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experience. Amanam I, Yao J, Puing A, Tsai NC, Samuels D, Ngo D, Ho S, Ali H, Aribi A, Arslan S, Artz A, Htut M, Koller P, Salhotra A, Sandhu K, Nikolaenko L, Pawlowska A, Shouse G, Stein A, Marcucci G, Forman S, Nakamura R, Dadwal S, Al Malki MM. Cancer Med. 2023 May;12(10):11248-11253. doi: 10.1002/cam4.5832. Epub 2023 Apr 20. PMID: 37081733 Free PMC article.
• The impact of SARS-CoV2 vaccines on the incidence of graft versus host disease in allogeneic hematopoietic stem cell transplant recipients: a single-center retrospective study. Ngo D, Chen J, Tinajero J, Aribi A, Arslan S, Marcucci G, Nakamura R, Al Malki MM, Forman SJ, Dadwal S, Ali H. Stem Cell Res Ther. 2023 Apr 18;14(1):95. doi: 10.1186/s13287-023-03326-3. PMID: 37072867 Free PMC article.
• Haploidentical Donor Blood or Marrow Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms: Results from a North American Collaboration. Jain T, Tsai HL, Elmariah H, Vachhani P, Karantanos T, Wall S, Gondek L, Bashey A, Keyzner A, Tamari R, Grunwald M, Abedin S, Nadiminti K, Iqbal M, Gerds A, Viswabandya A, McCurdy S, Malki MA, Varadhan R, Ali H, Gupta V, Jones RJ, Otoukesh S. Res Sq. 2023 Mar 21:rs.3.rs-2691216. doi: 10.21203/rs.3.rs-2691216/v1. Preprint. PMID: 36993719 Free PMC article.
• Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study. La Rosa C, Chiuppesi F, Park Y, Zhou Q, Yang D, Gendzekhadze K, Ly M, Li J, Kaltcheva T, Ortega Francisco S, Gutierrez MA, Ali H, Otoukesh S, Amanam I, Salhotra A, Pullarkat VA, Aldoss I, Rosenzweig M, Aribi AM, Stein AS, Marcucci G, Dadwal SS, Nakamura R, Forman SJ, Al Malki MM, Diamond DJ. Front Immunol. 2023 Mar 3;14:1114131. doi: 10.3389/fimmu.2023.1114131. eCollection 2023. PMID: 36936918 Free PMC article.
• High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions. Aldoss I, Afkhami M, Yang D, Gu Z, Mokhtari S, Shahani S, Pourhassan H, Agrawal V, Koller P, Arslan S, Tomasian V, Al Malki MM, Artz A, Salhotra A, Ali H, Aribi A, Sandhu KS, Ball B, Otoukesh S, Amanam I, Becker PS, Stewart FM, Curtin P, Smith E, Telatar M, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pullarkat V. Am J Hematol. 2023 Jun;98(6):848-856. doi: 10.1002/ajh.26908. Epub 2023 Mar 16. PMID: 36880203
• COVID and Cancer: A Complete 3D Advanced Radiological CT-Based Analysis to Predict the Outcome. Rahmanuddin S, Jamil A, Chaudhry A, Seto T, Brase J, Motarjem P, Khan M, Tomasetti C, Farwa U, Boswell W, Ali H, Guidaben D, Haseeb R, Luo G, Marcucci G, Rosen ST, Cai W. Cancers (Basel). 2023 Jan 20;15(3):651. doi: 10.3390/cancers15030651. PMID: 36765610 Free PMC article.
• Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab. Agrawal V, Pourhassan H, Tsai NC, Ngo D, Koller P, Malki MMA, Salhotra A, Ali H, Aribi A, Sandhu KS, Arslan S, Ball B, Otoukesh S, Amanam I, Artz A, Singh D, Becker PS, Stewart FM, Smith EP, Curtin P, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pullarkat V, Aldoss I. Transplant Cell Ther. 2023 May;29(5):314-320. doi: 10.1016/j.jtct.2023.01.017. Epub 2023 Jan 19. PMID: 36682470
• A critical review of belumosudil in adult and pediatric patients with chronic graft-versus-host disease. Salhotra A, Sandhu K, O'Hearn J, Ali H, Nakamura R, Modi BG. Expert Rev Clin Immunol. 2023 Mar;19(3):241-251. doi: 10.1080/1744666X.2023.2152330. Epub 2022 Nov 30. PMID: 36440483 Review.
• Role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia. Ladbury C, Semwal H, Hong D, Yang D, Hao C, Han C, Liu A, Marcucci G, Rosenthal J, Hui S, Salhotra A, Ali H, Nakamura R, Stein A, Al Malki M, Wong JYC, Dandapani S. Front Oncol. 2022 Oct 31;12:1017355. doi: 10.3389/fonc.2022.1017355. eCollection 2022. PMID: 36387179 Free PMC article.
• MPN-075 Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Low Versus Higher Baseline Platelet Counts: A Subgroup Analysis of Data From a Phase 2 Study. Yacoub A, Borate U, Rampal R, Ali H, Wang E, Gerds A, Hobbs G, Kremyanskaya M, Winton E, O'Connell C, Goel S, Oh S, Schiller G, Assad A, Erickson-Viitanen S, Zhou F, Daver N. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S324. doi: 10.1016/S2152-2650(22)01433-1. PMID: 36163982 Clinical Trial.
• Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML). Ball BJ, Arslan S, Koller P, Ngo D, Afkhami M, Salhotra A, Al-Malki M, Aribi A, Ali H, Sandhu K, Otoukesh S, Amanam I, Pourhassan H, Artz A, Curtin P, Stein A, Nakamura R, Marcucci G, Smith E, Pullarkat V, Aldoss I. Leuk Lymphoma. 2022 Dec;63(13):3232-3236. doi: 10.1080/10428194.2022.2116934. Epub 2022 Sep 10. PMID: 36089918 No abstract available.
• Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, George TI, Gundabolu K, Hexner E, Hobbs GS, Jain T, Jamieson C, Kaesberg PR, Kuykendall AT, Madanat Y, McMahon B, Mohan SR, Nadiminti KV, Oh S, Pardanani A, Podoltsev N, Rein L, Salit R, Stein BL, Talpaz M, Vachhani P, Wadleigh M, Wall S, Ward DC, Bergman MA, Hochstetler C. J Natl Compr Canc Netw. 2022 Sep;20(9):1033-1062. doi: 10.6004/jnccn.2022.0046. PMID: 36075392
• Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide. Al Malki MM, Palmer J, Tsai NC, Mokhtari S, Hui S, Tsai W, Aldoss I, Ali H, Aribi A, Cao T, Mei M, Sandhu KS, Siddiqi T, Forman SJ, Nakamura R, Marcucci G, Stein A, Wong JYC, Rosenthal J. Blood Adv. 2022 Jul 26;6(14):4098-4106. doi: 10.1182/bloodadvances.2022007264. PMID: 35838754 Free PMC article. Clinical Trial.
• Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL. Aldoss I, Yang D, Tomasian V, Mokhtari S, Jackson R, Gu Z, Telatar M, Yew H, Al Malki MM, Salhotra A, Khaled S, Ali H, Aribi A, Sandhu KS, Mei M, Arslan S, Koller P, Artz A, Aoun P, Gu D, Snyder D, Stewart FM, Curtin P, Stein AS, Pillai R, Marcucci G, Forman SJ, Pullarkat V, Nakamura R, Afkhami M. Blood Adv. 2022 Sep 13;6(17):4936-4948. doi: 10.1182/bloodadvances.2022007597. PMID: 35816633 Free PMC article.
• Total Marrow and Lymphoid Irradiation with Post-Transplantation Cyclophosphamide for Patients with AML in Remission. Stein AS, Al Malki MM, Yang D, Palmer JM, Tsai NC, Aldoss I, Ali H, Aribi A, Artz A, Dandapani S, Farol L, Hui S, Liu A, Nakamura R, Pullarkat V, Radany E, Rosenthal J, Salhotra A, Sanchez JF, Spielberger R, Marcucci G, Forman SJ, Wong J. Transplant Cell Ther. 2022 Jul;28(7):368.e1-368.e7. doi: 10.1016/j.jtct.2022.03.025. Epub 2022 Apr 6. PMID: 35398328 Clinical Trial.
• Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib. Arslan S, Ali H, Mei M, Marcucci G, Forman S, Nakamura R, Stein A, Al Malki MM. Bone Marrow Transplant. 2022 May;57(5):830-833. doi: 10.1038/s41409-022-01590-0. Epub 2022 Feb 22. PMID: 35194155 No abstract available.
• High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia. Pourhassan H, Yang D, Afkhami M, Pillai R, Ball B, Al Malki M, Salhotra A, Ali H, Artz A, Curtin P, Armenian S, Stein A, Forman SJ, Marcucci G, Pullarkat V, Nakamura R, Aldoss I. Am J Hematol. 2022 May;97(5):E171-E173. doi: 10.1002/ajh.26490. Epub 2022 Feb 11. PMID: 35132678 No abstract available.
• Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukemia. Salhotra A, Tsai NC, Zhang J, Ngo D, Aribi A, Sandhu K, Ball B, Al-Malki M, Ali H, Koller P, Artz A, Forman S, Nakamura R, Stein A, Marcucci G, Aldoss I, Pullarkat V. Br J Haematol. 2022 Mar;196(6):e71-e74. doi: 10.1111/bjh.17996. Epub 2021 Dec 21. PMID: 34931310 No abstract available.
• Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Otoukesh S, Elmariah H, Yang D, Clark MC, Siraj M, Ali H, Mogili K, Arslan S, Nishihori T, Nakamura R, Pidala J, Marcucci G, Forman SJ, Anasetti C, Al Malki MM, Bejanyan N. Transplant Cell Ther. 2022 Feb;28(2):111.e1-111.e8. doi: 10.1016/j.jtct.2021.11.012. Epub 2021 Nov 26. PMID: 34844022
• Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD. Meyers G, Hamadani M, Martens M, Ali H, Choe H, Dawson P, Harris AC, van Hooren E, Klaassen W, Leifer E, MacMillan ML, van Oosterhout Y, Perez L, Pusic I, Vo P, Levine JE. Bone Marrow Transplant. 2022 Feb;57(2):302-303. doi: 10.1038/s41409-021-01529-x. Epub 2021 Nov 23. PMID: 34815518 Free PMC article. No abstract available.
• Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens. Yao JM, Yang D, Clark MC, Otoukesh S, Cao T, Ali H, Arslan S, Aldoss I, Artz A, Amanam I, Salhotra A, Pullarkat V, Sandhu K, Stein A, Marcucci G, Forman SJ, Nakamura R, Al Malki MM. Bone Marrow Transplant. 2022 Feb;57(2):232-242. doi: 10.1038/s41409-021-01528-y. Epub 2021 Nov 20. PMID: 34802049 Free PMC article.